KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.1 million.

  • Neogenomics' Net Income towards Common Stockholders fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • Per Neogenomics' latest filing, its Net Income towards Common Stockholders stood at -$27.1 million for Q3 2025, which was up 39.84% from -$45.1 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Net Income towards Common Stockholders registered a high of -$14.3 million during Q4 2023, and its lowest value of -$49.4 million during Q1 2022.
  • In the last 3 years, Neogenomics' Net Income towards Common Stockholders had a median value of -$24.3 million in 2023 and averaged -$24.1 million.
  • Per our database at Business Quant, Neogenomics' Net Income towards Common Stockholders tumbled by 548.98% in 2021 and then skyrocketed by 49.76% in 2023.
  • Over the past 5 years, Neogenomics' Net Income towards Common Stockholders (Quarterly) stood at -$41.8 million in 2021, then skyrocketed by 45.67% to -$22.7 million in 2022, then skyrocketed by 36.85% to -$14.3 million in 2023, then declined by 6.97% to -$15.3 million in 2024, then plummeted by 53.28% to -$27.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$27.1 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$25.9 million in Q1 2025.